Not certain. L is mostly protected by exclusive use and Flaskwork patents. The Flaskwork patents aren’t quite as protective of L. Once L starts treating other indications, it will lose exclusive use protection, because other indications are not orphan designated. So, expect Direct to step in on other indications if L starts expanding its indication profile, because the L patent will likely only go to about 2026 if L loses orphan exclusive use protection. (Note: if these therapies are approved)
I hope I’m making sense.
Market Data 
Markets 
AI
